
An NIH-led team describes how a non-NMDA-blocking ketamine metabolite moved from back-translational discovery to 4 ongoing phase 2 trials.

Dr Thomas is a senior scientist at Precision Therapeutics & Translational Technologies.

An NIH-led team describes how a non-NMDA-blocking ketamine metabolite moved from back-translational discovery to 4 ongoing phase 2 trials.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.